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OBJECTIVE—Sirtuin 1 (SIRT1) is implicated in the regulation
of mitochondrial function, energy metabolism, and insulin sensi-
tivity in rodents. No studies are available in humans to demon-
strate that SIRT1 expression in insulin-sensitive tissues is
associated with energy expenditure and insulin sensitivity.
RESEARCH DESIGN AND METHODS—Energy expenditure
(EE), insulin sensitivity, and SIRT1 mRNA adipose tissue expres-
sion (n  81) were measured by indirect calorimetry, hyperin-
sulinemic-euglycemic clamp, and quantitative RT-PCR in 247
nondiabetic offspring of type 2 diabetic patients.
RESULTS—High EE during the clamp (r  0.375, P  2.8 
10
9) and high EE (EE during the clamp  EE in the fasting
state) (r  0.602, P  2.5  10
24) were associated with high
insulin sensitivity. Adipose tissue SIRT1 mRNA expression was
signiﬁcantly associated with EE (r  0.289, P  0.010) and with
insulin sensitivity (r  0.334, P  0.002) during hyperinsulinemic-
euglycemic clamp. Furthermore, SIRT1 mRNA expression corre-
lated signiﬁcantly with the expression of several genes regulating
mitochondrial function and energy metabolism (e.g., peroxisome
proliferator–activated receptor  coactivator-1, estrogen-
related receptor , nuclear respiratory factor-1, and mitochon-
drial transcription factor A), and with several genes of the
respiratory chain (e.g., including NADH dehydrogenase [ubiqui-
none] 1 subcomplex 2, cytochrome c, cytochrome c oxidase
subunit IV, and ATP synthase).
CONCLUSIONS—Impaired stimulation of EE by insulin and
low SIRT1 expression in insulin-sensitive tissues is likely to
reﬂect impaired regulation of mitochondrial function associated
with insulin resistance in humans. Diabetes 59:829–835, 2010
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ompromised mitochondrial function in skeletal
muscle predisposes to insulin resistance and
type 2 diabetes (1,2). In contrast, physical activ-
ity and weight loss in obese and sedentary
subjects stimulate mitochondrial biogenesis and improve
insulin sensitivity (3). Animal and human studies have
shown that mitochondrial function is associated with
insulin sensitivity, but the mechanisms explaining this
association are largely unknown (4).
The mammalian sirtuins (SIRT1–SIRT7) are implicated
in gene silencing, mitochondrial function, energy ho-
meostasis, insulin sensitivity, and longevity (5). We previ-
ously demonstrated that treatment with SIRT1 activator,
resveratrol, enhanced mitochondrial activity and pro-
tected mice from diet-induced obesity and insulin resis-
tance (4). The effects of resveratrol were seen in both
muscle and adipose tissue and resulted in an increase in
mitochondrial function, which translated into an increase
in energy expenditure (EE) and insulin sensitivity. Small
molecule activators of SIRT1, that are structurally unre-
lated to resveratrol, have also been shown to improve
insulin sensitivity, lower plasma glucose, and increase
mitochondrial capacity (6). In many rodent models
(4,7), the upregulation of the oxidative phosphorylation
(OXPHOS) pathway is coordinated by peroxisome prolif-
erator–activated receptor  coactivator (PGC) 1, which is
a target of SIRT1 (8). Similarly, insulin resistance in human
skeletal muscle has been associated with decreased mito-
chondrial oxidative capacity and ATP synthesis and de-
creased expression of genes that control mitochondrial
activity, including PGC-1 (9–11).
The offspring of type 2 diabetic subjects are known to be
insulin resistant, and they have defects in mitochondrial
OXPHOS associated with increased intramyocellular lipid
content (9). The association of EE and insulin sensitivity
with SIRT1 and PGC-1 mRNA expression has not been
previously investigated. Therefore, we studied here the
association of EE, insulin sensitivity, and adipose tissue
SIRT1 and PGC-1 mRNA expression in 247 nondiabetic
offspring of subjects with type 2 diabetes.
RESEARCH DESIGN AND METHODS
The subjects were selected from an ongoing study and included healthy
nondiabetic offspring of patients with type 2 diabetes, as previously described
(12). The diabetic patients (probands) were randomly selected among type 2
diabetic subjects living in the region of the Kuopio University Hospital.
Spouses of the probands had to have a normal glucose tolerance in an oral
glucose tolerance test (OGTT). The study protocol was approved by the ethics
committee of the University of Kuopio. All study subjects gave an informed
consent. A total of 247 offspring (one to three from each family) were studied.
Their mean  SD age was 35.1  6.3 years and BMI 26.3  4.7 kg/m
2.
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nearest 0.5 cm and 0.1 kg, respectively. BMI was calculated as weight (in
kilograms) divided by square of height (in meters). On the ﬁrst day, an OGTT
was performed with 75 g of glucose. Subjects with normal glucose tolerance
(n  210), isolated impaired fasting glucose (n  6), or impaired glucose
tolerance (n  31), deﬁned on the basis of the World Health Organization
criteria (13), were included in further studies. An intravenous glucose
tolerance test (IVGTT) was performed to determine the ﬁrst-phase insulin
release after an overnight fast. After baseline blood collection, a bolus of
glucose (300 mg/kg in a 50% solution) was given within 30 s into the
antecubital vein. Samples for the measurement of blood glucose and plasma
insulin (arterialized venous blood) were drawn at 5, 0, 2, 4, 6, 8, 10, 20, 30,
40, 50, and 60 min. After an IVGTT, the degree of insulin sensitivity was
evaluated with the hyperinsulinemic-euglycemic clamp technique (insulin
infusion rate of 40 mU  min
1  m
2 body surface area) as previously
described (14). Blood glucose was clamped at 5.0 mmol/l for the next 120 min
by infusion of 20% glucose at various rates according to blood glucose
measurements performed at 5-min intervals. The mean amount of glucose
infused during the last 20 min of the clamp was used to calculate the rates of
whole-body glucose uptake (WBGU) and divided with lean body mass (LBM)
for statistical analyses. Nonoxidative glucose metabolism (per LBM) was
calculated as the difference between the rates of WBGU/LBM and glucose
oxidation (per LBM). Indirect calorimetry was performed with a computerized
ﬂow-through canopy gas analyzer system (Deltatrac; Datex) as previously
described (14). The mean value of the data during the last 20 min of the clamp
was used to calculate glucose and lipid oxidation. Protein, glucose, and lipid
oxidation were calculated according to the method reported by Ferrannini
(15). A computed tomography scan (Siemens Volume Zoom) at the level of
fourth lumbal vertebra was performed to evaluate the amount of intra-
abdominal and subcutaneous fat as previously described (14). Blood and
plasma glucose were measured by the glucose oxidase method (Glucose and
Lactate Analyzer 2300 Stat Plus; Yellow Springs Instruments), and plasma
insulin was determined by radioimmunoassay (Phadeseph Insulin RIA 100,
Pharmacia Diagnostics; 125J RIA Kit, Incstar, respectively). Serum free fatty
acids (FFAs) were determined by an enzymatic method from Wako Chemi-
cals. Nonprotein urinary nitrogen was measured by the automated Kjeldahl
method as previously described (14). Plasma concentrations of tumor necro-
sis factor- and cytokines (interleukin [IL]-1 receptor antagonist [IL-1RA],
IL-6, IL-8, IL-10, IL-18, and interferon  and serum levels of soluble adhesion
molecules (intercellular adhesion molecule-1, vascular cell adhesion mole-
cule-1, e-selectin, and p-selectin) were measured with high-sensitivity assay
kits from R&D Systems. IL-8 was measured with a kit from Biosource
International. High-sensitivity C-reactive protein (hs-CRP) was measured with
an Immulite analyzer and a DPC hs-CRP assay.
Gene expression studies in offspring of type 2 diabetic parents. Subcu-
taneous fat needle biopsies were taken after an overnight fast in a supine
position at the level of the umbilicus during local anesthesia. Total RNA from
adipose tissue (n  81) was isolated with an RNeasy Lipid Tissue Mini kit
(Qiagen) and treated with DNase (DNA-free; Ambion). Total RNA from
skeletal muscle biopsies (n  11) was isolated with QIAzol (Qiagen) and
cleaned with an RNeasy Plus Micro Kit (Qiagen). RNA was transcribed to
cDNA using random primers and a High-Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems). Quantitative RT-PCRs were performed in a
seven 500 Real-Time PCR System (Applied Biosystems) using 6 ng (RNA
equivalents) of cDNA as template, gene-speciﬁc primers, and probes (Applied
Biosystems) (information on primers and probes available upon request).
Expression levels of different genes were normalized to large ribosomal
protein P0 (adipose tissue: Hs99999902_ml; Applied Biosystems) or to -actin
(skeletal muscle: Hs99999903_m1; Applied Biosystems) using the standard
curve method.
Sirt1 mRNA expression studies in mice. Total RNA was isolated from
adipose tissue samples of 5-month-old female transgenic (DBA/2  BALB/c)
mice using TRI reagent (Ambion), according to the manufacturer’s guidelines.
The resulting total RNA was subjected to DNase treatment using RNase-free
DNase (Ambion). The purity of isolated RNA was measured by a NanoDrop
spectrophotometer. A set concentration of RNA was reverse transcribed into
cDNA, and quantitative PCR was performed on ABI Prism 7500 Sequence
Detection System (Applied Biosystems). Inventoried Taqman primers for Sirt1
(Mm01168521_m1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(Mm99999915_g1) were purchased from Applied Biosystems. Sirt1 expression
was normalized to the copy number of GAPDH.
Sirt1 protein expression studies in mice. Adipose tissue samples were
homogenized and proteins extracted using T-PER (no. 78510; Pierce) along
with protease inhibitors and phosphatase inhibitors (Roche) from the same
mice as in mRNA expression studies. After homogenization, tissue lysates
were centrifuged for 30 min at high speed, and supernatant was collected and
stored at 70°C until further analysis. Protein concentrations were measured
with bicinchoninic acid protein assay kit (no. 23225; Pierce, Rockford, IL). A
total of 20 	g/lane of protein samples containing NuPAGE LDS sample buffer
(Invitrogen) and reducing agent were loaded into 4–12% NuPAGE Bis-Tris gels
(Invitrogen) and were subjected to gel electrophoresis and transferred to
polyvinylidene ﬂuoride membranes (Amersham). For Sirt1 proteins, the
membranes were blocked in Tris-buffered saline (TBS) with 3% milk and 0.05%
Tween-20 for1ha troom temperature, washed with TBS-0.05% Tween-20 for
3  5 min, and incubated overnight at 
4°C with SIRT1(no. 07-131; Millipore)
primary antibodies (1:1,000). The membranes were washed with TBS-0.05%
Tween-20 for 3  5 min before incubating them with secondary anti-rabbit
horseradish peroxidase–conjugated immunoglobulin (no. NA934V; GE Health
Care, Amersham, U.K.) (1:40,000) for2ha troom temperature. The mem-
branes were ﬁnally washed with TBS-0.05% Tween-20 for 3  5 min. For
GAPDH, the membranes were blocked in TBS with 5% milk and 0.1% Tween-20
f o r2ha troom temperature, washed with TBS-0.1% Tween-20 for 3  5 min,
and incubated with GAPDH (no. ab8245; Abcam) primary antibodies (1:5,000)
overnight at 
4°C. The membranes were washed with TBS-0.1% Tween-20 for
3  5 min before incubating them with secondary anti-mouse horseradish
peroxidase–conjugated immunoglobulin (no. NA931V; GE Health Care) (1:
10,000) in TBS-0.1% Tween-20 for1ha troom temperature. The membranes
were ﬁnally washed with TBS-0.1% Tween-20 for 3  5 min. The bands were
visualized using chemiluminescence (ECL plus; GE Health Care), and images
were captured in a Image Quant RT-ECL machine (version 1.0.1; GE Health
Care). Quantiﬁcation of the bands was done by applying Quantity One
software (Bio-Rad). Sirt1 protein expression was normalized to GAPDH
protein levels. The experiments were repeated four times.
Statistical analysis. Data analyses were carried out with SPSS 14.0 for
Windows. The results for continuous variables are given as means  SD.
Variables with skewed distribution (glucose, insulin, FFAs, and subcutaneous
and intra-abdominal fat) were logarithmically transformed for statistical
analyses. Linear regression was used to calculate the correlations. Uni-and
multivariate regression models were applied to assess the determinants of the
rates of the WBGU. Linear mixed-model analysis was applied to adjust for
confounding factors. For mixed-model analysis, we included the pedigree
(coded as a family number) as a random factor, the tertiles as ﬁxed factors,
and age as a covariate.
RESULTS
Energy expenditure and insulin sensitivity. EE during
the clamp positively correlated with insulin sensitivity
(r  0.375, P  2.8  10
9) (Fig. 1). Even stronger
correlation was found between insulin-stimulated energy
expenditure EE (deﬁned as EE during the clamp  EE in
the fasting state) and insulin sensitivity (r  0.602, P 
2.5  10
24). In contrast, fasting EE was not correlated
with insulin sensitivity (r  0.004). To further investigate
the association of EE and insulin sensitivity, we analyzed
the rates of WBGU/LBM during the hyperinsulinemic
clamp according to the tertiles of EE (Fig. 1). We did not
ﬁnd differences in WBGU among the tertiles of fasting EE,
glucose oxidation, or nonoxidative glucose disposal (data
not shown). In contrast, subjects in the highest tertile of
EE/LBM during the hyperinsulinemic clamp had highest
WBGU/LBM (49.85  15.43 vs. 55.02  15.46 vs. 63.44 
18.76 	mol/kg LBM/min, P  2.2  10
6), which was
attributable to both high-glucose oxidative (19.54  5.42
vs. 20.96  5.62 vs. 22.75  6.11 	mol/kg LBM/min, P 
0.007) and nonoxidative (30.31  12.81 vs. 34.06  13.24
vs. 40.68  16.52 	mol/kg LBM/min, P  1.2  10
5)
glucose disposal. These differences were even more pro-
nounced across the tertiles of EE/LBM, where subjects in
the highest tertile had highest WBGU/LBM (43.82  13.25
vs. 55.75  13.64 vs. 67.96  16.31 	mol/kg LBM/min, P 
2.5  10
20), attributable to both high-glucose oxidative
(17.51  4.34 vs. 20.81  5.45 vs. 24.58  5.31 	mol/kg
LBM/min, P  5.9  10
16) and nonoxidative (26.31 
12.08 vs. 34.94  12.24 vs. 43.38  15.16 	mol/kg LBM/min,
P  3.6  10
13) glucose disposal.
Subjects in the highest EE tertile used more glucose
for energy production than did subjects in the lower EE
SIRT1, ENERGY EXPENDITURE, INSULIN SENSITIVITY
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the fasting state (P  0.010) and during the hyperinsuline-
mic clamp (P  1.2  10
12) (Fig. 2). Subjects with the
highest EE had the lowest lipid oxidation in the fasting
state (P  1.6  10
4) and during the hyperinsulinemic
clamp (P  9.2  10
9). In the fasting state, FFA levels
were not different among the tertiles (P  0.417), whereas
during the hyperinsulinemic clamp, subjects with the
highest EE had the lowest levels of FFAs (0.05  0.03 vs.
0.04  0.02 vs. 0.03  0.03 mmol/l, P  8.7  10
7).
To evaluate variables associated with the rates of
WBGU/LBM during the hyperinsulinemic clamp, we per-
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FIG. 1. A: Correlation between the rates of WBGU and fasting EE (univariate linear regression). Correlation between the rates of WBGU and EE
during the hyperinsulinemic clamp (B) and correlation between the rates of WBGU and EE (deﬁned as EE during the clamp  EE in the fasting
state) (C). Rates of WBGU in the lowest (f), middle (o), and highest () EE tertiles according to fasting EE (D), EE during the hyperinsulinemic
clamp (E), and the EE (F). Data are means  SD (D–F).
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High EE exhibited the strongest association with high
WBGU/LBM, followed by low levels of low intra-abdomi-
nal adipose tissue mass and low total triglycerides. Low
lipid oxidation during the hyperinsulinemic clamp and low
subcutaneus adipose tissue mass were also associated
with insulin sensitivity. In multivariate regression analy-
ses, a model including EE and intra-abdominal adipose
tissue as independent variables explained a higher propor-
tion of the variance of WBGU/LBM (R
2  0.431, P  1.7 
10
24) than did EE alone (R
2  0.362), but adding age
and sex into this model did not improve substantially the
R
2 value (R
2  0.436, P  5.4  10
23). A model that
included EE and subcutaneous adipose tissue mass as
independent variables was not more strongly associated
with WBGU/LBM (R
2  0.379, P  8.0  10
21) than was
EE alone.
SIRT1 mRNA expression correlation with EE, insulin
sensitivity, and SIRT1 target genes. To explore the
determinants of insulin-stimulated EE and WBGU/LBM,
we measured adipose tissue mRNA expression of SIRT1
and PGC-1. SIRT1 mRNA expression correlated signiﬁ-
cantly with EE (r  0.289, P  0.010) and with WBGU/LBM
(r  0.334, P  0.002) during the euglycemic clamp (Fig.
3). No statistically signiﬁcant correlation was found be-
tween SIRT1 expression and EE in the fasting state (r 
0.142). The correlation between SIRT1 expression and
PGC-1 expression was 0.448 (P  3.5 10
5). PGC-1
expression correlated signiﬁcantly only with WBGU/LBM
(r  0.387, P  3.9 10
4) but not with EE during the
clamp (r  0.167).
We also measured adipose tissue mRNA levels of sev-
eral target genes of SIRT1 and PGC-1 (Table 2). SIRT1
mRNA expression correlated signiﬁcantly with PGC-1
expression, estrogen-related receptor (ERR) , nuclear
respiratory factor-1 (NRF-1), mitochondrial transcription
factor A (TFAM), catalase (CAT), and with several genes
of the respiratory chain, including NADH dehydrogenase
(ubiquinone) 1 subcomplex 2, cytochrome c, cytochrome
c oxidase subunit IV, and ATP synthase. SIRT1 mRNA
expression also correlated with the expression of soluble
superoxide dismutase 1. The correlations of mRNA ex-
pression of these genes with PGC-1 expression were
quite similar but somewhat weaker. Neither SIRT1 mRNA
expression nor PGC-1 mRNA expression correlated with
superoxide dismutase 2.
SIRT1 mRNA expression correlation in adipose tis-
sue and skeletal muscle. In 11 subjects who had both
adipose tissue and skeletal muscle biopsy, the correlation
of SIRT1 mRNA expression in these tissues was 0.655
(P  0.029). Mitochrondial DNA in skeletal muscle also
correlated positively with SIRT mRNA expression in
adipose tissue (r  0.519) and skeletal muscle (r 
0.533), although the correlations were not statistically
signiﬁcant due to a small sample size (supplemental Table 2
in the online appendix [available at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-1191/DC1]).
SIRT1 mRNA expression correlation with cytokines
and adhesion molecules. SIRT mRNA expression nega-
tively correlated with hs-CRP (r  0.241, P  0.039), but
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FIG. 2. A: Respiratory quotient in the fasting state and during the
hyperinsulinemic-euglycemic clamp in the tertiles of EE. Data are
means  SD in the lowest (f), middle (o), and highest () tertile.
Lipid oxidation in the fasting state and during the hyperinsulinemic-
euglycemic clamp in the tertiles of EE (B) and FFAs in the fasting
state and during the hyperinsulinemic-euglycemic clamp in the tertiles
of EE (C). Data are means  SD.
TABLE 1
Variables associated with the rates of WBGU/LBM (univariate
linear regression model, n  247)
Independent variable
Standardized
coefﬁcient R
2 P value
EE (clamp  fasting) 0.602 0.362 2.5  10
24
Intra-abdominal adipose tissue 0.497 0.247 3.1  10
14
Total triglycerides 0.480 0.230 1.3  10
15
Lipid oxidation/LBM during
the clamp 0.438 0.192 1.7  10
12
Subcutaneus adipose tissue 0.338 0.114 6.8  10
7
EE/LBM in the fasting state 0.004 0.000 0.946
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molecules were almost entirely nonsigniﬁcant (supple-
mentary Table 1).
Sirt1 mRNA and protein correlation. Subcutaneous
adipose tissue from 5-month-old female mice was obtained
and used for quantitative RT-PCR and Western blot anal-
yses. We observed a strong correlation between Sirt1
mRNA and Sirt1 protein expression levels (r  0.882, P 
0.001) (Fig. 4).
DISCUSSION
Our study demonstrated that insulin-stimulated increase in
EE was strongly associated with insulin sensitivity in
offspring of patients with type 2 diabetes. Furthermore, we
showed for the ﬁrst time that adipose tissue SIRT1 mRNA
expression correlated with EE and insulin sensitivity
during hyperinsulinemia. Moreover, SIRT1 expression cor-
related with the expression of several genes regulating the
mitochondrial function.
In our study, high EE during hyperinsulinemia, and
particularly high EE, were strongly associated with insu-
lin-stimulated WBGU/LBM. These results agree with pre-
vious studies (16,17) including relatively small samples of
lean and obese subjects. Hyperinsulinemic clamp simu-
lates the postprandial state with high insulin levels that
promote the glucose ﬂux from circulating blood into
insulin sensitive tissues. An 8-h insulin infusion in humans
has been shown to increase mitochondrial mRNA tran-
script levels, mitochondrial protein synthesis, and ATP
production (18). This response was, however, blunted in
type 2 diabetic patients. In another study (19), diabetic
patients exhibited lower ATP production rate in response
to high-dose insulin infusion compared with that in non-
diabetic individuals. Thus, impaired mitochondrial ﬁtness
could be a consequence of impaired insulin action as
supported by a study in mice fed a high-fat, high-sucrose
diet showing that mitochondrial alterations do not precede
the onset of insulin resistance (20). In agreement with this
notion, a recent study (21) in mice demonstrated a direct
effect of SIRT1 on insulin sensitivity by repressing PTP1B.
Whether this mechanism is working also in humans needs
to be shown.
Alternatively, primary mitochondrial dysfunction could
lead to insulin resistance. An attractive possibility to
explain a causal link between impaired mitochondrial
function and insulin resistance is the hypothesis that
impaired OXPHOS capacity leads to intramyocellular lipid
accumulation (9) and thus impaired insulin signaling and
insulin resistance (22). High lipid levels in the circulating
blood impair insulin-stimulated ATP production in humans
(23). We observed that subjects with low insulin-stimu-
lated EE also had higher levels of FFAs, higher lipid
oxidation, and lower respiratory quotient during the hy-
perinsulinemic clamp, reﬂecting changes in fuel selection
in these subjects, which often lead to insulin resistance.
Further evidence supporting the hypothesis that mito-
chondrial activity stimulated by SIRT1 might be important
for energy metabolism and insulin action are high corre-
lations of adipose tissue SIRT1 mRNA expression with
expression of genes regulating mitochondrial function.
SIRT1 mRNA expression correlated signiﬁcantly with
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FIG. 3. A: Correlation of adipose tissue SIRT1 mRNA expression level
with EE during the hyperinsulinemic clamp. B: Correlation of adipose
tissue SIRT1 mRNA expression level with the rates of whole-body
glucose uptake in offspring of type 2 diabetic patients.
TABLE 2
Pearson correlations between adipose tissue mRNA expression
of SIRT1 and PGC-1 with adipose tissue mRNA expression of
genes regulating mitochondrial function (n  81)
SIRT1 PGC-1
PGC-1 r  0.358 r  0.152
P  0.001 P  0.179
NRF1 r  0.286 r  0.235
P  0.010 P  0.036
ERR r  0.339 r  0.260
P  0.002 P  0.021
TFAM r  0.379 r  0.213
P  0.001 P  0.059
NDUFA2 r  0.392 r  0.273
P  3.5  10
4 P  0.015
CYCS r  0.263 r  0.159
P  0.019 P  0.161
COX4I1 r  0.332 r  0.262
P  0.003 P  0.020
ATP5G1 r  0.248 r  0.196
P  0.027 P  0.084
SOD1 r  0.460 r  0.348
P  2.0  10
5 P  0.002
SOD2 r  0.046 r  0.009
P  0.689 P  0.940
CAT r  0.350 r  0.422
P  0.002 P  1.3  10
4
Expression of all genes was normalized to RPL0 expression.
ATP5G1, ATP synthase, H 
 transporting, mitochondrial F0 com-
plex, subunit C1; CAT, catalase; COX4I1, cytochrome c oxidase
subunit IV isoform 1; CYCS, cytochrome c, somatic; NDUFA2, NADH
dehydrogenase (ubiquinone) 1  subcomplex 2; SOD1, superoxide
dismutase 1, soluble; SOD2, superoxide dismutase 2, mitochondrial.
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tions with PGC-1 in inducing genes related to OXPHOS
(24). Signiﬁcant correlations of SIRT1 mRNA expression
were also observed with ERR, which mediates many of
the downstream effects of activated PGC-1 on mitochon-
drial function (25), with NRF-1, which is an ERR/PGC-1
target, and with TFAM, which is a target of NRF-1 (26).
Furthermore, SIRT1 mRNA levels correlated with expres-
sion of several genes regulating the respiratory chain.
SIRT1 mRNA expression level also correlated with the
expression of soluble superoxide dismutase 1, which
protects the cell from superoxide toxicity, and with cata-
lase, which catalyzes the decomposition of hydrogen per-
oxide to water and oxygen (27). Because the accumulation
of reactive oxygen species can induce insulin resistance
(28), the role of SIRT1 in governing superoxide dismutase
1 and catalase expression could cooperate with the effects
of SIRT1 on the control of OXPHOS to improve insulin
sensitivity. Our ﬁndings are also in agreement with recent
studies in mice (4,29). Transgenic mice overexpressing
SIRT1 (30) or mice having SIRT1 activity enhanced by the
administration of the SIRT1 agonist, resveratrol (4,29), or
a small molecule activator of SIRT1 (6), were both leaner,
more hypermetabolic, and showed favorable effects on
glucose and lipid metabolism. Mice treated with SRT1720,
a potent synthetic activator of SIRT1, enhanced insulin
sensitivity (31). Furthermore, in human studies a SIRT1
activator (SRT501) has been shown to improve glucose
control (32). Adipose tissue SIRT1 mRNA expression was
negatively associated with hs-CRP level, which is in agree-
ment with the anti-inﬂammatory effect of SIRT1 (33). The
correlation of adipose tissue SIRT1 mRNA with other
inﬂammatory markers was modest. This may reﬂect a
poorer correlation of SIRT1 mRNA with plasma levels of
cytokines compared with cytokine expression in adipose
tissue.
SIRT1 mRNA expression in adipose tissue had a high
correlation with skeletal muscle SIRT1 mRNA (r  0.655).
Therefore, we believe that our results obtained in adipose
tissue reﬂect metabolic changes in skeletal muscle, which
is the main tissue for EE and insulin sensitivity during
insulin stimulation. Skeletal muscle mitochondrial DNA
correlated closely with SIRT1 mRNA expression in skele-
tal muscle and adipose tissue, giving evidence that upregu-
lation of the genes regulating mitochondrial biogenesis in
adipose tissue and likely to reﬂect corresponding changes
in skeletal muscle (Table 2). Finally, we demonstrated in
mice that Sirt mRNA expression and Sirt1 protein levels
were highly correlated (Fig. 4), demonstrating that our
results are likely to be valid also at protein level. However,
the limitation of our study is that we could not determine
SIRT1 protein level from adipose tissue biopsies due to a
small amount of tissue that we can obtain using needle
biopsy techniques.
In summary, we demonstrated that insulin-stimulated
EE is strongly associated with insulin-stimulated glucose
uptake in offspring of subjects with type 2 diabetes.
Impaired stimulation of EE by insulin is likely to reﬂect
impaired regulation of mitochondrial function in insulin-
resistant states. This could be at least partially explained
by low expression of SIRT1 and PGC-1, two important
master regulators of mitochondrial activity. Even though it
is not possible to determine the primary defect from our
cross-sectional data, disturbance in mitochondrial func-
tion and low EE were strongly associated with impaired
insulin-stimulated glucose uptake. Our results give evi-
dence that activating SIRT1 could be one of the potential
mechanisms to treat insulin resistance and patients with
type 2 diabetes.
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